Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Digital Realty Trust, Inc. (DLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Digital Realty Trust, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Digital Realty Trust, Inc. trades at $174.96 (market cap $64.71B). The key difference: Digital Realty Trust, Inc. is far larger — about 14.4× ACADIA Pharmaceuticals Inc.'s market cap, and Digital Realty Trust, Inc. pays a 2.79% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DLR | |
|---|---|---|
Market Cap | $4.49B | $64.71B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $203.91 |
52-Week Low | $20.06 | $147.93 |
Enterprise Value | $3.69B | $82.23B |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DLR trades at $174.9, up 0.92% today, with a bearish technical signal but strong analyst buy consensus. The stock shows robust revenue growth, with 2025 revenue at $6.11B and net income margin of 21.73%, though valuation ratios like P/E of 46.07 appear elevated. Recent news highlights a $7.8B data center acquisition from Blackstone, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $219.08, but risks include high debt levels, execution challenges from recent acquisitions, and competitive pressures. The stock offers growth exposure to data center infrastructure, supported by institutional confidence, yet investors should weigh valuation concerns against expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →
